Últimas noticias sobre Simulations Plus (NASDAQ:SLP) Bolsa

Simulations Plus

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Stuttgart,,Germany,-,07-01-2023:,Person,Holding,Cellphone,With,Logo,Of

Pre-Market Outlook

DVLT

EQBK

FAST

Las acciones de Fastenal, Datavault AI y FB Financial destacan en una jornada con futuros a la baja en Wall Street.

Wall Street abre en rojo: atención a Fastenal, Datavault AI y otras acciones clave del día

Fear and Greed

WDFC

El índice Fear &amp; Greed marca &#34;codicia extrema&#34;, pero Wall Street cierra a la baja tras nuevos aranceles y balances mixtos.

El S&amp;P 500 registra pérdida semanal en medio de nervios por aranceles de Trump

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Markets

Trading Ideas

NMTC

SGMO

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: AMS, GES, NMTC, SLP y SGMO.

5 acciones en el foco este viernes: AMS, GES, NMTC, SLP y SGMO

Simulations Plus Inc

Smooth Love Potion - United States Dollar

SIMPLEX HLDGS INC by SIMPLEX HLDGS INC.

Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares declined on Tuesday following the release of its third-quarter 2025 earnings report.
The company reported sales of $20.4 million, representing a 10% year-over-year increase, but this fell short of the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate of $20.9 million</a>.
This miss followed preliminary third-quarter sales figures released in June, which were already lower than expectations at $19 million to $20 million, compared to a consensus of $22.78 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44764201/whats-going-on-with-charles-river-certara-simulations-plus-stocks-on-friday" rel="noreferrer noopener">What&#8217;s Going On With Charles River, Certara, Simulations Plus Stocks On Friday?</a>
Despite the revenue miss, Simulations Plus reported adjusted earnings of 45 cents per share, compared to <a href="https://www.benzinga.com/pressreleases/25/07/b46403848/simulations-plus-reports-third-quarter-fiscal-2025-financial-results" target="_blank" rel="noreferrer noopener">27 cents a year ago</a>.
Revenue breakdown showed a 6% increase in software revenue to $12.6 million and a 17% increase in services revenue to $7.7 million. The company&#8217;s gross profit stood at $13.0 million, achieving a 64% margin.
However, the quarter saw a substantial net loss of $67.3 million, resulting in a loss per share of $3.35. This was primarily due to a non-cash impairment charge of $77.2 million, contrasting sharply with a net income of $3.1 million and diluted EPS of $0.15 in the prior year.
Adjusted EBITDA was $7.4 million, representing 37% of total revenue, up from $5.6 million (30% of total revenue) in the same period last year.
Looking ahead, Simulations Plus revised its fiscal 2025 adjusted earnings guidance to $0.93 to $1.06, down from the previous <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44635451/simulations-plus-reports-second-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">guidance of $1.07 to $1.20</a>.
Similarly, the company&#8217;s <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45912081/simulations-plus-slashes-guidance-amid-biotech-spending-cuts-analyst-expresses-doubt" rel="noreferrer noopener">fiscal 2025 sales forecast</a> was adjusted in June to $76 million to $80 million, a reduction from the prior guidance of $90 million to $93 million and below the consensus of $82.9 million.
The anticipated adjusted EBITDA margin for fiscal 2025 also saw a downward revision, now expected to be between 23% and 27%, compared to the earlier guidance of 31% to 33%.
In June, Simulations Plus initiated a restructuring of its operations, including <a target="_blank" href="https://www.benzinga.com/secfilings/25/06/45718737/simulations-plus-inc-general-corporate-statement-form8" rel="noreferrer noopener">workforce reductions</a> and cost-cutting measures, aimed at improving operational efficiency and reducing expenses.
William Blair analysts noted that the company&#8217;s outlook remains unchanged since June. They attribute the ongoing cautious spending by biopharma clients to uncertainties surrounding future funding, drug pricing, and potential tariffs, leading to budget cuts, project cancellations, and work postponements.
Analyst Max Smock highlighted, &#8220;While the software business remains somewhat resilient (expectation for 5% to 9% organic segment growth in fiscal 2025), we have begun to see some signs of potential softening as we head into fiscal 2026&#8230;&#8221;
In response to the challenging market, KeyBanc downgraded Simulations Plus from Overweight to Sector Weight. Analyst Scott Schoenhaus commented, &#8220;While we believe these challenges affect SLP more sharply given its customer concentration and biotech exposure, we also thought there would be opportunities with the most recent Proficiency acquisition that gave us hope that organic revenue growth could re-accelerate toward high-single digits next year (FY26) off easier comps.&#8221;
KeyBanc anticipates continued weak customer demand in the near to mid-term, with no clear signs of a biotech market rebound. This makes predicting a recovery difficult and a higher valuation hard to justify, prompting the firm to significantly cut its estimates and lower its valuation target to account for these risks and uncertainties.
Price Action: SLP stock is trading lower by 25% to $13.10 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46422474/polymarket-home-free-as-trump-led-doj-closes-biden-initiated-probes" target="_blank" rel="noreferrer noopener">Polymarket Home Free As Trump-Led DOJ Closes Biden-Initiated Probes</a></li>
</ul>

Analyst Color

Guidance

Downgrades

Health Care

Analyst Ratings

Movers

General

Simulations Plus Sees Weaker Demand Persist, Outlook Softens

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 400.0% to $16.55 during Tuesday's regular session. The company's market cap stands at $5.2 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 99.62% to $5.28. The market value of their outstanding shares is at $2.6 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 65.66% to $1.14. The company's market cap stands at $11.5 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares rose 34.23% to $0.92. The company's market cap stands at $3.6 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 20.0% to $3.96. The company's market cap stands at $9.2 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock increased by 18.16% to $5.61. The company's market cap stands at $919.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares fell 38.8% to $0.43 during Tuesday's regular session. The company's market cap stands at $27.4 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares decreased by 29.09% to $28.8. The company's market cap stands at $161.8 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares decreased by 24.79% to $13.14. The market value of their outstanding shares is at $351.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 24.22% to $0.7. The market value of their outstanding shares is at $1.9 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock declined by 18.94% to $1.75. The company's market cap stands at $3.1 million. </li>
<li>Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) stock declined by 14.23% to $3.77. The company's market cap stands at $189.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYCC

INKT

KAPA

KYTX

LIXT

PLRZ

RANI

SSII

SXTP

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Nasdaq gaining more than 100 points on Tuesday.
The Dow traded down 0.57% to 44,204.33 while the NASDAQ gained 0.71% to 20,786.86. The S&amp;P 500 also rose, gaining, 0.01% to 6,269.15.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46413798/morgan-stanley-how-to-earn-500-a-month-from-q2-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q2 Earnings</a>
Leading and Lagging Sectors Information technology shares jumped by 1.6% on Tuesday.
In trading on Tuesday, materials stocks dipped by 0.9%.
Top Headline
Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) reported better-than-expected second-quarter adjusted EPS results.
Wells Fargo posted adjusted earnings of $1.54 per share, beating market estimates of $1.40 per share. Wells Fargo reported a net interest income of $11.71 billion on Tuesday, down 2% year over year in the second quarter of 2025.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares shot up 143% to $6.43 after the company announced it has entered into a definitive merger agreement with True Health.</li>
<li>Shares of Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) got a boost, surging 87% to $1.2808 after the company announced safety results from its Phase 2 trial of ENV-105 in advanced prostate cancer.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares were also up, gaining 57% to $0.2366 after the company announced it is partnering with HYPERCOMMUNITY to deliver an AI-driven VTuber platform.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Ryvyl Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) shares dropped 45% to $0.3552 after the company announced the pricing of its $6 million offering of 15,384,615 shares and warrants at $0.39 per share and accompanying warrant.</li>
<li>Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) were down 42% to $0.4058 after the company announced the pricing of $3.0 million registered direct offering.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) was down, falling 19% to $14.15 following downbeat quarterly sales. Keybanc downgraded the stock from Overweight to Sector Weight and Stephens &amp; Co. cut its price target from $28 to $20.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $66.66 while gold traded down 0.1% at $3,355.90.
Silver traded down 1.2% to $38.280 on Tuesday, while copper fell 0.3% to $5.5320.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.09%, while Spain's IBEX 35 Index fell 1.16%. London's FTSE 100 fell 0.23%, Germany's DAX 40 slipped 0.09% and France's CAC 40 fell 0.21% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei gaining 0.55%, Hong Kong's Hang Seng gaining 1.60%, China's Shanghai Composite falling 0.42% and India's BSE Sensex gaining 0.39%.
Economics
The New York Empire State Manufacturing Index jumped to 5.5 in July, compared to a reading of -16.0 in June and topping market estimates of -9.0.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46414893/meta-to-rally-around-8-here-are-10-top-analyst-forecasts-for-tuesday">Meta To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

BLMZ

RVYL

Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday.
Shares of Simulations Plus, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) fell sharply in pre-market trading after the company reported downbeat third-quarter sales and cut its <a href="https://www.benzinga.com/quote/SLP/earnings">FY2025 EPS guidance</a>.
Simulations Plus reported quarterly earnings of 45 cents per share which beat the analyst consensus estimate of 7 cents pers hare. The company reported quarterly sales of $20.363 million which missed the analyst consensus estimate of $20.878 million.
Keybanc analyst Scott Schoenhaus downgraded Simulations Plus from Overweight to Sector Weight.
Simulations Plus shares dipped 6.3% to $16.37 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) shares dipped 29.9% to $9.55 in pre-market trading after jumping 166% on Monday. The company announced the pricing of a $2.05 million registered direct offering of 170,830 shares at $12.00 per share.</li>
<li>MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) declined 27.5% to $29.45 in pre-market trading after dipping 37% on Monday. William Blair analyst Matt Phipps, on Monday, downgraded MiNK Therapeutics from Outperform to Market Perform.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) dropped 26.7% to $3.29 in pre-market trading after gaining over 4% on Monday.</li>
<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) fell 20.7% to $5.38 in pre-market trading.</li>
<li>Sequans Communications S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) declined 10.8% to $5.01 in pre-market trading. Sequans shares gained around 20% on Monday after the company announced it bought 683 more Bitcoins and provided updates on its total holdings.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) declined 5.5% to $1.8990 in pre-market trading.</li>
<li>FB Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) fell 5.4% to $46.50 in pre-market trading following downbeat quarterly sales.</li>
<li>ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) fell 4.6% to $3.52 in pre-market trading. ProKidney filed for common stock offering of up to $200 million.</li>
<li>Blue Gold Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGL#NASDAQ">BGL</a>) declined 4.5% to $26.60 in pre-market trading after surging 30% on Monday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

IOVA

MDXG

ORGO

PROK

SQFT

SQNS

Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

WIIM

Simulations Plus shares are trading lower after Keybanc downgraded the stock from Overweight to Sector Weight and Stephens & Co. cut its price target from $28 to $20.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Scott Schoenhaus downgraded the rating for Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) from Overweight to Sector Weight. Simulations Plus shares closed at $17.47 on Monday. <a href="https://www.benzinga.com/quote/slp/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Derek Podhaizer downgraded Atlas Energy Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) from Overweight to Neutral and maintained the price target of $16. Atlas Energy Solutions shares closed at $13.98 on Monday. <a href="https://www.benzinga.com/quote/aesi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst John Colantuoni downgraded the rating for DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) from Buy to Hold but raised the price target from $235 to $250. DoorDash shares closed at $242.85 on Monday. <a href="https://www.benzinga.com/quote/dash/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Stephen Tusa downgraded Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) from Overweight to Neutral and maintained the price target of $79. Carrier Global shares closed at $76.61 on Monday. <a href="https://www.benzinga.com/quote/carr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andrew Rosivach downgraded the rating for Realty Income Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) from Outperform to Peer Perform. Realty Income shares closed at $58.70 on Monday. <a href="https://www.benzinga.com/quote/o/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CARR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/CARR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15082000/image-176-1024x575.png" alt="" class="wp-image-985851" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15082000/image-176-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15082000/image-176-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15082000/image-176-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15082000/image-176.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday"> JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

AESI

CARR

DASH

This Carrier Global Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

In the last three months, 4 analysts have published ratings on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.5, a high estimate of $36.00, and a low estimate of $20.00. This current average represents a 31.17% decrease from the previous average price target of $38.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1752580831_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Simulations Plus's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Simulations Plus. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Simulations Plus compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Simulations Plus's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Simulations Plus's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SLP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Simulations Plus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Simulations Plus</h2>
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
<h3>Simulations Plus: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Simulations Plus displayed positive results in 3M. As of 28 February, 2025, the company achieved a solid revenue growth rate of approximately 22.55%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Simulations Plus's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.7%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.64%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Simulations Plus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.54%, the company showcases efficient use of assets and strong financial health.
Debt Management: Simulations Plus's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Simulations Plus: 4 Analysts Share Their Views

Stephens &amp; Co. analyst Jeff Garro maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight and lowers the price target from $28 to $20.

Price Target

Stephens & Co. Maintains Overweight on Simulations Plus, Lowers Price Target to $20

Shares of The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) rose sharply in pre-market trading following the announcement <a href="https://www.benzinga.com/markets/equities/25/07/46407569/the-trade-desk-shares-spike-15-after-hours-heres-why-the-stock-is-trending-tonight">of its inclusion in the S&amp;P 500 index.</a>
This development comes after the S&amp;P Dow Jones Indices revealed that The Trade Desk would replace ANSYS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANSS#NASDAQ">ANSS</a>) in the S&amp;P 500, effective from the market open on July 18.
Trade Desk shares jumped 14.8% to $86.60 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) climbed 122% to $3.73 in pre-market trading after dipping 27% on Monday.</li>
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) surged 101.5% to $5.33 in pre-market trading after the company announced a merger with THPlasma and the termination of its transaction with 20/20 BioLabs.</li>
<li>60 Degrees Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) jumped 89% to $4.09 in pre-market trading after falling 15% on Monday.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) rose 63.9% to $0.2477 in pre-market trading after the company announced it is partnering with HYPERCOMMUNITY to deliver an AI-driven VTuber platform.</li>
<li>Brazil Potash Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRO#NYSE">GRO</a>) jumped 52.4% to $2.21 in pre-market trading after the company signed an MoU with Fictor &amp; WTT S.A., outlining terms for Fictor Energia to fund approximately $200 million in power transmission construction costs for the Autazes Project.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 38.7% to $4.59 in pre-market trading after dipping over 10% on Monday.</li>
<li>Movano Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) gained 30% to $0.7135 in pre-market trading after dipping 21% on Monday.</li>
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) gained 20% to $4.71 in pre-market trading after dipping 30% on Monday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 18% to $14.99 in pre-market trading after gaining 10% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>LQR House Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) declined 35% to $2.99 in pre-market trading. LQR House filed for common stock offering of $46 million.</li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) dipped 33.6% to $1.60 in pre-market trading. S&amp;W announced voluntary delisting from Nasdaq and SEC deregistration.</li>
<li>TROOPS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROO#NASDAQ">TROO</a>) dipped 29.9% to $0.94 in pre-market trading after gaining 105% on Monday.</li>
<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) shares tumbled 29.9% to $9.55 in pre-market trading after jumping 166% on Monday. The company announced the pricing of a $2.05 million registered direct offering of 170,830 shares at $12.00 per share.</li>
<li>MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) fell 27.5% to $29.45 in pre-market trading after dipping 37% on Monday. William Blair analyst Matt Phipps, on Monday, downgraded MiNK Therapeutics from Outperform to Market Perform.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) fell 26.7% to $3.29 in pre-market trading after gaining over 4% on Monday.</li>
<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) declined 20.7% to $5.38 in pre-market trading.</li>
<li>Australian Oilseeds Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOT#NASDAQ">COOT</a>) fell 15% to $0.4405 in pre-market trading after gaining over 5% on Monday.</li>
<li>Sequans Communications S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) fell 10.8% to $5.01 in pre-market trading. Sequans shares gained around 20% on Monday after the company announced it bought 683 more Bitcoins and provided updates on its total holdings.</li>
<li>Simulations Plus, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares fell 6.3% to $16.37 in pre-market trading after the company reported downbeat third-quarter sales and cut its FY2025 EPS guidance.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

ANSS

COOT

HTOO

MOVE

SANW

TROO

Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Keybanc analyst Scott Schoenhaus downgrades Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) from Overweight to Sector Weight.

Keybanc Downgrades Simulations Plus to Sector Weight

Simulations Plus Invests $1M In Clinical Development Technology Company Nurocor

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) lowers FY2025 Adj EPS guidance from $1.07-$1.20 to $0.93-$1.06 vs $0.32 analyst estimate. Affirms FY2025 sales outlook from $76.000 million-$80.000 million to $76.000 million-$80.000 million vs $82.968 million estimate.

Simulations Plus Lowers FY2025 Adj EPS Guidance from $1.07-$1.20 to $0.93-$1.06 vs $0.32 Est; Affirms FY2025 Sales Guidance of $76.000M-$80.000M vs $82.968M Est

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.07 by 516.44 percent. This is a 136.84 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $20.363 million which missed the analyst consensus estimate of $20.878 million by 2.47 percent. This is a 9.81 percent increase over sales of $18.544 million the same period last year.

Earnings Beats

Earnings Misses

Simulations Plus Q3 Adj. EPS $0.45, Sales $20.363M Miss $20.878M Estimate

Keybanc analyst Scott Schoenhaus maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight and lowers the price target from $40 to $25.

Keybanc Maintains Overweight on Simulations Plus, Lowers Price Target to $25

U.S. stock futures were lower on Monday after ending on a negative note on Friday. Futures of major benchmark indices were lower.
President Donald Trump, in a telephone interview with NBC News' &#8220;Meet the Press&#8221; moderator Kristen Welker, asserted that &#8220;The tariffs have been very well received.&#8221; He believes that if a 10% tariff can generate around $300 billion annually, a 20% rate could <a href="https://www.benzinga.com/news/politics/25/07/46386524/trump-wants-blanket-tariffs-of-up-to-20-after-surprise-treasury-surplus-in-june-ed-yardeni-says-don">double that intake</a>. 
Meanwhile, the European Union was ready with a prepared list of tariffs worth 21 billion euros ($24.52 billion) on U.S. goods if the two sides fail to reach a trade deal, reported Reuters, highlighting Italy&#8217;s Foreign Minister Antonio Tajani&#8216;s comments. 
He also issued, latest threats to impose a <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46384885/peter-schiff-gives-trumps-30-tariff-threa">30% tariff on all imports</a> from Mexico and the EU. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) scaled fresh highs on Monday as the cryptocurrency hit a fresh high of $123,091.61 per coin.
The 10-year Treasury bond yielded 4.42% and the two-year bond was at 3.89%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool&#8217;s</a> projections show markets pricing a 93.3% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.32%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.31%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.31%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.38%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Monday. The SPY was down 0.27% at $621.94, while the QQQ declined 0.27% to $552.73, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
On Friday, while most sectors on the S&amp;P 500 closed lower, notably financial, health care, and materials stocks recorded the steepest declines, energy and consumer discretionary stocks defied the broader market downturn, concluding the session higher.
This mixed performance occurred a day after the S&amp;P 500 reached a new record high, ultimately leading U.S. stocks to settle lower.
The broader market reflected these losses over the past week, with the Dow Jones dropping 1% and the S&amp;P by 0.3%.
Fueling market jitters, Trump signaled a more aggressive trade stance, announcing a 35% tariff on Canadian imports effective Aug. 1, alongside proposed blanket duties of 15% to 20% on most other trading partners.
In corporate news, WD-40 Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) reported better-than-expected earnings for its third quarter, though its sales figures fell short of estimates.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.22%</td>
<td>20,585.53</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.33%</td>
<td>6,259.75</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.63%</td>
<td>44,371.51</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.26%</td>
<td>2,234.83</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Jim Cramer in an X post reflected his concern over tariffs linked to Trump&#8217;s policies.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Back to the old pattern of woe off of Trump.. The whole tariff thing will be &quot;fine&quot; until it implodes of there is endless re-trading &#8230;
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1944575812734157284?ref_src=twsrc%5Etfw">July 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Ed Yardeni from Yardeni Research highlighted the surplus of just over <a href="https://www.benzinga.com/news/politics/25/07/46386524/trump-wants-blanket-tariffs-of-up-to-20-after-surprise-treasury-surplus-in-june-ed-yardeni-says-don">$27 billion in June</a>, reported by the U.S. Treasury Department, saying that Trump "must have loved the headline… ‘Treasury posts unexpected surplus in June as tariff receipts surge."
However, he warned that tariffs are essentially "a tax on U.S. importers," which can erode corporate profit margins and profits. While rebounding productivity growth might offer some offset, the potential impact on businesses remains a significant concern.
Adding about the market reaction to tariffs, Yardeni said, &#8220;The selloffs in the bond and stock markets back then forced Trump to deescalate his trade war. That's not happening now—not so far at least. This undoubtedly is emboldening Trump.&#8221;
Speculating on how the financial markets will respond this week to his latest escalation, Yardeni said that perhaps investors have learned that Trump's huffing and puffing is simply the way he negotiates trade deals.
&#8220;They are betting that it will work and result in lots of deals. They've also learned that Trump can change his mind often. So if some trade deals aren't coming together fast enough, he'll settle on a vague letter of understanding to work out a deal over time.&#8221;
The risk for the economy and investors is that Trump has concluded that if the financial markets aren't going to be vigilant about his trade war, then he can proceed with it unchecked, explained Yardeni. &#8220;If so, then TTT (Trump&#8217;s Tariff Turmoil) will last past the summer.&#8221;
Yardeni said in a LinkedIn <a href="https://www.linkedin.com/pulse/trumps-reign-tariffs-aint-over-edward-yardeni-eshve/">post</a>, &#8220;Then again, investors may agree with our current view that &#8216;this too shall pass&#8217; by the end of the summer: The economy will remain resilient, and inflation will remain surprisingly moderate. It all adds up to a relatively normal seasonal pattern, with the stock market weak during the late summer through the fall followed by a year-end rally to 6500 in our scenario.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul class="wp-block-list">
<li>No significant data is scheduled to be released on Monday.</li>
<li>On Tuesday, June&#8217;s headline and core consumer price index data, and the Empire State manufacturing survey will be released by 8:30 a.m. ET.</li>
<li>Fed Governor Michelle Bowman will speak at 9:15 a.m., Fed Governor Michael Barr will speak at 12:45 p.m., Boston Fed President Susan Collins will speak at 2:45 p.m., and Dallas Fed President Lorie Logan will speak at 6:45 p.m. ET.</li>
<li>On Wednesday, June&#8217;s headline and core producer price index data will be out by 8:30 a.m. ET.</li>
<li>June&#8217;s industrial production and capacity utilization will be announced by 9:15 a.m. ET.</li>
<li>Federal Reserve Governor Michael Barr will speak again at 10:00 a.m., Fed&#8217;s beige book data will be out by 2:00 p.m., and New York Fed President John Williams will speak at 6:30 a.m. ET.</li>
<li>On Thursday, the initial jobless claims data for the week ended July 5, June retail sales, import price index, and Philadelphia Fed manufacturing survey will all be out by 8:30 a.m. ET.</li>
<li>May&#8217;s business inventories data and July&#8217;s home builder confidence index data will be out by 10:00 a.m. ET.</li>
<li>Fed Governor Adriana Kugler will speak at 10:00 a.m., San Francisco Fed President Mary Daly will speak at 12:45 p.m., Fed Governor Lisa Cook will speak at 1:30 p.m., and Fed Governor Christopher Waller will speak at 6:30 p.m. ET.</li>
<li>On Friday, June&#8217;s housing starts and building permits data will be out by 8:30 a.m., and preliminary consumer sentiment data for July will be released by 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) was up 3.41%, Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose 1.76%, Riot Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) advanced 3.86%, MARA Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) was 4.75% higher, along with all the other Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46385840/michael-saylors-strategy-coinbase-mara-riot-and-other-crypto-related-stocks-spike-after-hours-as-bitcoin-touches-all-time-high-beyond-122000">exposed stocks</a> as the cryptocurrency hit a fresh high of $123,091.61 on Monday.</li>
<li>Datavault AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) jumped 15.64% in premarket on Monday after the company entered into a licensing deal with IBM for program subscriptions.</li>
<li>BIT Mining Ltd. ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) surged 40.40% after it announced strategic expansion into the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) ecosystem, marking a significant shift in the company&#8217;s growth strategy. The cryptocurrency mining company plans to establish an SOL treasury of up to $300 million.</li>
<li>Sequans Communications SA ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) climbed 14.67% after closing a $384 million strategic investment to launch a Bitcoin treasury initiative last week. The financing consists of a $195 million PIPE (Private Investment in Public Equity) and $189 million in convertible debentures due July 7, 2028.</li>
<li>Fastenal Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) was up 2.94% as analysts expect it to report earnings of 28 cents per share on revenue of $2.07 billion before the opening bell.</li>
<li>FB Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) was unchanged as it is expected to report earnings after the closing bell. Analysts estimate earnings of 88 cents per share on revenue of $136.32.</li>
<li>Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) was 5.07% higher as analysts expect it to report earnings of 7 cents per share on revenue of $20.88 million after the closing bell</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.72% to hover around $68.94 per barrel.
Gold Spot US Dollar rose 0.33% to hover around $3,367.09 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.09% at the 97.9400 level.
Asian markets ended on a mixed note on Monday, as India's S&amp;P BSE Sensex, Japan's Nikkei 225, and Australia's ASX 200 indices fell. While China&#8217;s CSI 300, Hong Kong's Hang Seng, and South Korea's Kospi indices rose. European markets were mostly lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46386524/trump-wants-blanket-tariffs-of-up-to-20-after-surprise-treasury-surplus-in-june-ed-yardeni-says-dont-push-your-luck">Trump Wants Blanket Tariffs Of Up To 20% After Surprise Treasury Surplus In June: Ed Yardeni Says &#8216;Don&#8217;t Push Your Luck&#8217;</a></li>
</ul>
Photo courtesy: godongphoto / Shutterstock.com

$BTC

$SOL

BTCM

COIN

MARA

MSTR

RIOT

US Stocks Likely To Open Lower As Trump's 20% Blanket Tariff Bombshell Weighs On Markets: Bitcoin-Linked Stocks MSTR, COIN Jump As BTC Touches $123,000

<h3>Companies Reporting Before The Bell</h3>
• Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $2.06 billion. 
<h3>Companies Reporting After The Bell</h3>
• Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $20.36 million. 
• FB Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) is likely to report quarterly earnings at $0.88 per share on revenue of $135.90 million. 
• Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) is projected to report quarterly earnings at $0.89 per share on revenue of $59.72 million. 
• Jewett-Cameron Trading (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCTC#NASDAQ">JCTC</a>) is expected to report earnings for its third quarter. 
• SPDR ICE Preferred Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSK#NYSE">PSK</a>) is likely to report earnings for its second quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JCTC

Earnings Scheduled For July 14, 2025

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Fastenal Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) to report quarterly earnings at 28 cents per share on revenue of $2.07 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Fastenal shares gained 1% to $43.70 in after-hours trading.</li>
<li>Analysts are expecting FB Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) to have earned 88 cents per share on revenue of $136.32 million after the closing bell. FB Financial shares slipped 0.02% to $43.21 in the after-hours trading session.</li>
<li>Datavault AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) shares rose sharply in after-hours trading on Friday after the company entered into a licensing deal with IBM for program subscriptions. Datavault AI shares jumped 26.1% to $0.8938 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>After the markets close, Equity Bancshares Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NASDAQ">EQBK</a>) is projected to post quarterly earnings at 89 cents per share on revenue of $60.46 million. Equity Bancshares shares fell 1.1% to close at $42.93 on Friday.</li>
<li>Analysts expect Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) to post quarterly earnings at 7 cents per share on revenue of $20.88 million after the closing bell. Simulations Plus shares gained 2.8% to $17.44 in after-hours trading.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Photo via Shutterstock

Fastenal, FB Financial And 3 Stocks To Watch Heading Into Monday

The CNN Money Fear and Greed index showed a slight decline in the overall market sentiment, while the index remained in the &#8220;Extreme Greed&#8221; zone on Friday.
U.S. stocks settled lower on Friday, a day after the S&amp;P 500 notched a fresh record high. Wall Street recorded losses last week, with the Dow Jones falling 1% and the S&amp;P down by 0.3%.
President Donald Trump signaled a more aggressive trade stance. Trump last week announced a 35% tariff on Canadian imports starting Aug. 1 and blanket duties of 15% to 20% on most other trading partners.
WD-40 Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) posted better-than-expected earnings for its third quarter, while sales missed estimates.
Most sectors on the S&amp;P 500 closed on a negative note, with financial, health care and materials stocks recording the biggest losses on Friday. However, energy and consumer discretionary stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by 279 points to 44,371.51 on Friday. The S&amp;P 500 fell 0.33% to 6,259.75, while the Nasdaq Composite slipped 0.22% to 20,585.53 during Friday's session.
Investors are awaiting earnings results from Fastenal Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>), FB Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) and Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 75.3, the index remained in the &#8220;Extreme Greed&#8221; zone on Friday, versus a prior reading of 75.7.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a> </li>
</ul>
Photo courtesy: Shutterstock

S&P 500 Records Weekly Loss Amid Trump Tariff Jitters: Fear & Greed Index Remains In 'Extreme Greed' Zone

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Simulations Plus will report an earnings per share (EPS) of $0.26.
The market awaits Simulations Plus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 7.83% increase in the share price the next day.
Here's a look at Simulations Plus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.26</td>
<td>0.17</td>
<td>0.03</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.31</td>
<td>0.17</td>
<td>0.06</td>
<td>0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-7.000000000000001%</td>
<td>-9.0%</td>
<td>-15.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1752242497_0.png" alt="eps graph" />
<h3>Simulations Plus Share Price Analysis</h3>
Shares of Simulations Plus were trading at $17.57 as of July 10. Over the last 52-week period, shares are down 58.91%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analysts' Take on Simulations Plus</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Simulations Plus.
The consensus rating for Simulations Plus is Buy, derived from 3 analyst ratings. An average one-year price target of $33.67 implies a potential 91.63% upside.
<h3>Peer Ratings Comparison</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Health Catalyst, Definitive Healthcare and OptimizeRx, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Health Catalyst, with an average 1-year price target of $6.0, suggesting a potential 65.85% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Definitive Healthcare, with an average 1-year price target of $3.4, suggesting a potential 80.65% downside.</li>
<li>Analysts currently favor an Buy trajectory for OptimizeRx, with an average 1-year price target of $14.17, suggesting a potential 19.35% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
In the peer analysis summary, key metrics for Health Catalyst, Definitive Healthcare and OptimizeRx are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simulations Plus</td>
<td>Buy</td>
<td>22.55%</td>
<td>$13.13M</td>
<td>1.64%</td>
</tr>
<tr>
<td>Health Catalyst</td>
<td>Buy</td>
<td>6.28%</td>
<td>$36.23M</td>
<td>-6.40%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>-6.76%</td>
<td>$43.76M</td>
<td>-27.95%</td>
</tr>
<tr>
<td>OptimizeRx</td>
<td>Buy</td>
<td>11.37%</td>
<td>$13.34M</td>
<td>-1.89%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Simulations Plus ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating. However, it has the lowest Return on Equity compared to its peers.
<h3>All You Need to Know About Simulations Plus</h3>
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
<h3>Key Indicators: Simulations Plus's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Simulations Plus displayed positive results in 3 months. As of 28 February, 2025, the company achieved a solid revenue growth rate of approximately 22.55%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Simulations Plus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.7% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.64%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Simulations Plus's ROA stands out, surpassing industry averages. With an impressive ROA of 1.54%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Simulations Plus's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SLP/earnings">To track all earnings releases for Simulations Plus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Simulations Plus's Earnings Forecast

Simulations Plus is reaffirming the preliminary revenue for its third fiscal quarter and full year 2025 revenue guidance which was previously provided on June 11, 2025.
<ul>
<li>The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million</li>
<li>Full year fiscal 2025 revenue is expected to range between $76 million and $80 million</li>
</ul>

Simulations Plus Reaffirms Q3 FY2025 Revenue of $19M–$20M And Full-Year Revenue Of $76M–$80M

Press Releases

Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date

Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

Simulations Plus Releases DILIsym® 11

Simulations Plus Releases ADMET Predictor® 13

Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue

Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum

Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call

Comments

Simulations Plus

Noticias

Últimas noticias sobre Simulations Plus (NASDAQ:SLP) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL